A F DAVITA LOGO DAVITA LOGO
DaVita, Inc. company logo. (PRNewsFoto)[AS]
TORRANCE, CA USA
EL SEGUNDO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- DaVita Inc.
(NYSE: DVA), today announced it received a copy of a civil complaint filed
in U.S. District Court for the Central District of California by plaintiff
Sheet Metal Workers National Health Fund. The complaint names as defendants
Amgen, Inc., Fresenius Medical Care Holdings, Inc. and DaVita Inc. The
complaint, which has not yet been served on DaVita, is styled as a request
for class action and alleges claims against DaVita relating to the
administration and use of Epogen(R). The complaint's principal allegations
against DaVita are that Epogen(R) was administered to hemodialysis patients
intravenously, as opposed to subcutaneously, and that Epogen(R) was
DaVita administers Epogen(R) only pursuant to a physician's order, and
the physician determines both the dosage amount and route of administration
of Epogen(R). Also, the FDA-approved package insert for Epogen(R)
recommends that Epogen(R) be administered intravenously for patients on
hemodialysis. DaVita intends to vigorously defend the plaintiffs' claims
and allegations contained in the complaint.
DaVita is a leading provider of dialysis services for patients
suffering from chronic kidney failure. DaVita operates and provides
administrative services to approximately 1,300 outpatient dialysis centers
located in 42 states and the District of Columbia, serving approximately
SOURCE DaVita Inc.